InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company

(Image Credit: AdobeStock/Hairem)

InflammX Therapeutics, Inc. has entered into an option agreement granting Bausch + Lomb the right to acquire the company. InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.

Under the terms of the option agreement, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on the achievement of specified development milestones.¹

“We see tremendous potential in combining our resources and expertise with InflammX’s innovative approach to retinal disease treatment,” said Yehia Hashad, chief medical officer and executive vice president of Research & Development, Bausch + Lomb in the press release.¹

Brian Levy, chief executive officer, InflammX Therapeutics shared insight into this decision and the potential outcomes, saying, “Partnering with Bausch + Lomb offers a unique opportunity to accelerate the development of our pipeline and bring our therapies to patients worldwide. We share a common vision of improving outcomes for individuals affected by retinal disease, such as iAMD, which represents a majority of patients diagnosed with AMD, and for which there is no currently approved treatment.”¹

The agreement was signed in December 2024. No financial terms have been disclosed.¹

Reference:

1. InflammX Therapeutics Announces Option Agreement with Bausch + Lomb. InflammX Therapeutics Inc. January 10, 2025. Accessed January 13, 2025. https://www.globenewswire.com/news-release/2025/01/10/3007691/0/en/InflammX-Therapeutics-Announces-Option-Agreement-with-Bausch-Lomb.html